Logo image of IMAB

I-MAB-SPONSORED ADR (IMAB) Stock Fundamental Analysis

NASDAQ:IMAB - US44975P1030 - ADR

4.5 USD
-0.68 (-13.13%)
Last: 8/27/2025, 8:00:02 PM
4.56 USD
+0.06 (+1.33%)
After Hours: 8/27/2025, 8:00:02 PM
Fundamental Rating

3

Overall IMAB gets a fundamental rating of 3 out of 10. We evaluated IMAB against 547 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IMAB as it has an excellent financial health rating, but there are worries on the profitability. IMAB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IMAB has reported negative net income.
IMAB had negative earnings in 4 of the past 5 years.
In the past 5 years IMAB reported 4 times negative operating cash flow.
IMAB Yearly Net Income VS EBIT VS OCF VS FCFIMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B -2B -2.5B

1.2 Ratios

Looking at the Return On Assets, with a value of -18.22%, IMAB is in the better half of the industry, outperforming 78.98% of the companies in the same industry.
IMAB's Return On Equity of -19.14% is amongst the best of the industry. IMAB outperforms 85.56% of its industry peers.
Industry RankSector Rank
ROA -18.22%
ROE -19.14%
ROIC N/A
ROA(3y)-42.75%
ROA(5y)-32.49%
ROE(3y)-60.9%
ROE(5y)-45.09%
ROIC(3y)N/A
ROIC(5y)N/A
IMAB Yearly ROA, ROE, ROICIMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

IMAB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMAB Yearly Profit, Operating, Gross MarginsIMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K

More info and screens

8

2. Health

2.1 Basic Checks

IMAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IMAB has been increased compared to 1 year ago.
Compared to 5 years ago, IMAB has more shares outstanding
IMAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMAB Yearly Shares OutstandingIMAB Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IMAB Yearly Total Debt VS Total AssetsIMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

An Altman-Z score of 13.67 indicates that IMAB is not in any danger for bankruptcy at the moment.
The Altman-Z score of IMAB (13.67) is better than 89.03% of its industry peers.
There is no outstanding debt for IMAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.67
ROIC/WACCN/A
WACC9.69%
IMAB Yearly LT Debt VS Equity VS FCFIMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

IMAB has a Current Ratio of 22.86. This indicates that IMAB is financially healthy and has no problem in meeting its short term obligations.
IMAB's Current ratio of 22.86 is amongst the best of the industry. IMAB outperforms 95.61% of its industry peers.
A Quick Ratio of 22.86 indicates that IMAB has no problem at all paying its short term obligations.
IMAB's Quick ratio of 22.86 is amongst the best of the industry. IMAB outperforms 95.61% of its industry peers.
Industry RankSector Rank
Current Ratio 22.86
Quick Ratio 22.86
IMAB Yearly Current Assets VS Current LiabilitesIMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 89.81% over the past year.
The Revenue for IMAB has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)89.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.65%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 10.71% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y69.91%
EPS Next 2Y28.48%
EPS Next 3Y15.33%
EPS Next 5Y10.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMAB Yearly Revenue VS EstimatesIMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2028 2029 2030 2031 2032 0 500M 1B 1.5B
IMAB Yearly EPS VS EstimatesIMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMAB Price Earnings VS Forward Price EarningsIMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMAB Per share dataIMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

IMAB's earnings are expected to grow with 15.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.48%
EPS Next 3Y15.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

I-MAB-SPONSORED ADR

NASDAQ:IMAB (8/27/2025, 8:00:02 PM)

After market: 4.56 +0.06 (+1.33%)

4.5

-0.68 (-13.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-20 2025-08-20/bmo
Earnings (Next)N/A N/A
Inst Owners13.08%
Inst Owner Change4.27%
Ins Owners0.79%
Ins Owner ChangeN/A
Market Cap367.47M
Analysts83.64
Price Target6.32 (40.44%)
Short Float %2.01%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.51%
Min EPS beat(2)-61.76%
Max EPS beat(2)54.75%
EPS beat(4)1
Avg EPS beat(4)-12.75%
Min EPS beat(4)-61.76%
Max EPS beat(4)54.75%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.33%
PT rev (3m)12.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)29.42%
EPS NY rev (1m)-13.46%
EPS NY rev (3m)-96.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.87
P/tB 1.87
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS2.41
TBVpS2.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.22%
ROE -19.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.75%
ROA(5y)-32.49%
ROE(3y)-60.9%
ROE(5y)-45.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.86
Quick Ratio 22.86
Altman-Z 13.67
F-ScoreN/A
WACC9.69%
ROIC/WACCN/A
Cap/Depr(3y)76.01%
Cap/Depr(5y)97.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.65%
EPS Next Y69.91%
EPS Next 2Y28.48%
EPS Next 3Y15.33%
EPS Next 5Y10.71%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-161.06%
EBIT Next 3Y34.96%
EBIT Next 5Y74.68%
FCF growth 1Y56.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.04%
OCF growth 3YN/A
OCF growth 5YN/A